What is Leerink Partnrs’ Forecast for TVTX FY2026 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities research analysts at Leerink Partnrs upped their FY2026 earnings per share estimates for Travere Therapeutics in a report released on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of $0.63 for the year, up from their prior estimate of $0.52. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.90) per share.

Several other research firms have also issued reports on TVTX. Piper Sandler increased their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Scotiabank lifted their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a research note on Wednesday. Evercore ISI raised their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday. Cantor Fitzgerald initiated coverage on Travere Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating for the company. Finally, Canaccord Genuity Group raised their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.77.

Travere Therapeutics Trading Up 1.0 %

Shares of Travere Therapeutics stock opened at $23.43 on Thursday. The firm’s 50-day moving average price is $19.06 and its two-hundred day moving average price is $15.95. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -5.09 and a beta of 0.72. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $25.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jennison Associates LLC bought a new stake in shares of Travere Therapeutics during the 4th quarter worth $14,222,000. abrdn plc purchased a new position in Travere Therapeutics in the fourth quarter valued at about $6,829,000. Prudential Financial Inc. grew its position in shares of Travere Therapeutics by 60.5% during the 4th quarter. Prudential Financial Inc. now owns 969,141 shares of the company’s stock valued at $16,882,000 after acquiring an additional 365,200 shares during the period. Emerald Advisers LLC raised its holdings in shares of Travere Therapeutics by 19.8% in the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after purchasing an additional 323,513 shares during the period. Finally, Impax Asset Management Group plc purchased a new position in Travere Therapeutics in the fourth quarter valued at approximately $5,226,000.

Insider Activity

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP William E. Rote sold 2,437 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the completion of the sale, the senior vice president now directly owns 83,170 shares of the company’s stock, valued at $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 218,425 shares of company stock worth $4,674,259 over the last three months. 3.75% of the stock is currently owned by insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.